CLINICAL TRIALS PROFILE FOR AMIFAMPRIDINE PHOSPHATE
✉ Email this page to a colleague
All Clinical Trials for amifampridine phosphate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01377922 ↗ | A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) | Completed | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2011-06-01 | A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS). |
| NCT02189720 ↗ | Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS) | No longer available | Catalyst Pharmaceuticals, Inc. | 1969-12-31 | The primary objective of the study is: • To provide patients with CMSaccess to amifampridine phosphate therapy until the product becomes commercially available or development is discontinued. The secondary objective of the study is: • To assess the long-term safety of amifampridine phosphate in patients with CMS | |
| NCT02562066 ↗ | Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes | Completed | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2016-01-01 | This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment. |
| NCT02970162 ↗ | Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) | Completed | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2016-11-01 | This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study. |
| NCT03304054 ↗ | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | Completed | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2018-04-18 | Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis. |
| NCT03579966 ↗ | Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) | Active, not recruiting | Catalyst Pharmaceuticals, Inc. | Phase 3 | 2018-07-01 | Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amifampridine phosphate
Condition Name
Clinical Trial Locations for amifampridine phosphate
Trials by Country
Clinical Trial Progress for amifampridine phosphate
Clinical Trial Phase
Clinical Trial Sponsors for amifampridine phosphate
Sponsor Name
